| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
human 5-HT1F Receptor ( IC50 = 0.006 μM ); human 5-HT1A Receptor ( IC50 = 0.530 μM ); human 5-HT1B Receptor ( IC50 = 0.549 μM );
human 5-HT1D Receptor ( IC50 = 0.575 μM ); human 5-HT1E Receptor ( IC50 = 1.415 μM ); human 5-HT2B Receptor ( IC50 = 1.695 μM ); Human 5-HT2A Receptor ( IC50 = 3.499 μM ); Human 5-HT3A Receptor ( IC50 = 3.935 mM ); Human 5-HT7 Receptor ( IC50 = 4.851 μM ); rat α2-adrenergic receptor ( IC50 = 3.69 μM ); rat α1-adrenergic receptor ( IC50 = 5.06 μM ) LY 344864 selectively targets the 5-HT1F receptor, a G protein-coupled serotonin receptor subtype. It binds with high affinity (Ki = 6 nM) and acts as a full agonist at this receptor. Activation of 5-HT1F receptors is associated with inhibition of neurogenic inflammation and vasodilation in the trigeminovascular system, which is implicated in migraine pathophysiology. Unlike other 5-HT1 receptor agonists (e.g., triptans), 5-HT1F agonists do not cause vasoconstriction, offering a potentially safer profile for migraine treatment. The compound shows selectivity for 5-HT1F over other serotonergic and non-serotonergic receptors. |
|---|---|
| ln Vitro |
LY 344864 binds to human 5-HT1F, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT3A, 5-HT2B, 5-HT2C, and 5-HT7, as well as rat α1-adrenergic and rat α2-adrenergic receptors with Kis of 0.006, 0.530, 0.549, 0.575, 1.415, 3.935, 1.695, 3.499, 4.851, 5.06 and 3.69 μM, respectively[1]. LY 344864 is a inducer of mitochondrial biogenesis[2].
In vitro, LY 344864 demonstrates high affinity binding to the 5-HT1F receptor with a Ki of 6 nM. As a full agonist, it activates receptor-mediated signaling pathways, including inhibition of adenylyl cyclase and modulation of neuronal excitability. The compound shows selectivity for 5-HT1F over other serotonin receptor subtypes and non-serotonergic targets. In cellular assays, LY 344864 activates 5-HT1F receptor-mediated G protein signaling, leading to downstream effects on cAMP levels and neuronal function. The compound's in vitro profile supports its use as a tool for studying 5-HT1F receptor pharmacology. |
| ln Vivo |
LY 344864 (0-10 ng/kg; oral or intravenous; once) inhibits neurogenic dural inflammation in a rat migraine model [1]. LY 344864 (1 mg/kg; intravenous injection; once) can cross the blood-brain barrier to a certain extent in rats [1]. LY 344864 (2 mg/kg; i.p.; daily for 14 days) attenuates dopaminergic neuron loss and improves behavioral endpoints in a mouse model of Parkinson's disease [2]. Animal model: Male Wistar rat, migraine model [1] Dosage: 1-10 ng/kg (oral), 0.3-2 ng/kg (intravenous injection) Administration method: oral, 75 minutes before trigeminal nerve stimulation or intravenously Injection, stimulation results 10 minutes before trigeminal nerve stimulation: When injected intravenously 10 minutes before stimulation, it can inhibit inflammation, with an ID50 (median infectious dose) of 0.6 ng/kg. When administered orally 75 minutes before trigeminal nerve stimulation, an ID50 of 1.2 ng/kg was obtained. Animal model: Male C57BL/6 mice, Parkinson's disease model [2] Dose: 2 mg/kg Administration: intraperitoneal injection, starting 7 days after injury, daily for 14 days Results: Compared with vehicle, Attenuated TH-ir loss in the striatum and substantia nigra-treated lesioned animals also increased locomotor activity in 6-hydroxydopamine-lesioned mice, whereas vehicle treatment had no effect.
In vivo, LY 344864 has been studied in preclinical models of migraine and central serotonergic signaling. Intracerebroventricular microinjection of LY 344864 inhibits methamphetamine-induced conditioned place preference reinstatement in rats. The compound exhibits oral activity and can penetrate the blood-brain barrier to some extent, enabling central nervous system target engagement. In animal models of migraine, 5-HT1F receptor agonists like LY 344864 inhibit neurogenic inflammation and dural vasodilation without causing vasoconstriction. The compound's in vivo profile supports the development of 5-HT1F-targeted antimigraine agents. |
| Enzyme Assay |
In vitro receptor binding assays for LY 344864 are performed using membrane preparations from cells expressing recombinant human 5-HT1F receptors. Radiolabeled ligands such as [3H]-5-HT or [3H]-LSD are used. Membranes are incubated with varying concentrations of LY 344864 in assay buffer at room temperature for 60-90 minutes. Bound and free radioligands are separated by rapid filtration through glass fiber filters. Filter-bound radioactivity is quantified by liquid scintillation counting. Ki values are calculated using the Cheng-Prusoff equation. Selectivity is assessed by screening against a panel of serotonergic and non-serotonergic receptors, transporters, and ion channels.
|
| Cell Assay |
In vitro cellular assays for LY 344864 are performed using cell lines expressing recombinant human 5-HT1F receptors, such as CHO or HEK-293 cells. Cells are cultured in appropriate medium and seeded in 96-well plates. Cells are treated with serial dilutions of LY 344864 (0.001-10 microM) for 15-30 minutes. Intracellular cAMP levels are measured using a competitive ELISA or HTRF-based detection kit following forskolin stimulation. Agonist activity is determined by the compound's ability to inhibit forskolin-stimulated cAMP accumulation. EC₅0 values are calculated from dose-response curves using nonlinear regression. Potency, efficacy (relative to serotonin), and selectivity are characterized.
|
| Animal Protocol |
Male Wistar rats, migraine pain model
1-10 ng/kg (oral), 0.3-2 ng/kg (intravenous) Oral, 75 minutes before trigeminal stimulation or intravenous, 10 minutes before trigeminal stimulation In vivo animal studies for LY 344864 are conducted in rodent models to study serotonin signaling and migraine mechanisms. In typical protocols, rats or mice are administered LY 344864 orally, intraperitoneally, or via intracerebroventricular injection at doses of 0.1-10 mg/kg. Behavioral tests such as conditioned place preference, locomotor activity, and pain responses are assessed. In migraine models, dural blood vessel permeability and trigeminal nerve activation are measured. Brain serotonin levels and metabolite concentrations are analyzed. Pharmacokinetic parameters are determined from plasma and brain tissue samples. The compound's effects on behavior and neurochemical markers are characterized. |
| ADME/Pharmacokinetics |
LY 344864 (CAS#: 186544-26-3) has molecular formula C21H22FN3O and molecular weight 351.42. The chemical name is (R)-N-[3-(dimethylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl]-4-fluorobenzamide. The compound is soluble in DMSO at ≥90 mg/mL. LY 344864 is a selective 5-HT1F receptor agonist (Ki = 6 nM) that has been used as a prototype compound for developing antimigraine agents. The compound is supplied as a research chemical for laboratory use only. Storage should be at -20degC, protected from light and moisture.
|
| Toxicity/Toxicokinetics |
Toxicological information for LY 344864 is limited as the compound is a research chemical. Based on its mechanism as a 5-HT1F receptor agonist, potential adverse effects may include those associated with serotonergic modulation. The compound should be handled with standard laboratory precautions including the use of personal protective equipment and working in a well-ventilated area. Avoid inhalation, ingestion, and skin contact. The compound should be stored at -20degC and disposed of according to institutional guidelines for chemical waste.
|
| References |
|
| Additional Infomation |
N-[(6R)-6-(dimethylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-yl]-4-fluorobenzamide is a member of the carbazole class of compounds.
LY 344864 (CAS#: 186544-26-3) is a selective and orally active 5-HT1F receptor agonist with a Ki of 6 nM. It is a full agonist that produces effects similar in magnitude to serotonin itself. The compound has been widely used in preclinical research to study migraine mechanisms and central serotonergic signaling. LY 344864 served as a prototype compound supporting the development of later 5-HT1F-targeted antimigraine agents and remains a valuable pharmacological research tool. Unlike triptans, 5-HT1F agonists do not cause vasoconstriction, offering a potentially safer profile for migraine treatment. As of the current date, LY 344864 is not approved as a therapeutic drug and is supplied for research use only. |
| Molecular Formula |
C21H22FN3O
|
|---|---|
| Molecular Weight |
351.43
|
| Exact Mass |
351.174
|
| Elemental Analysis |
C, 71.77; H, 6.31; F, 5.41; N, 11.96; O, 4.55
|
| CAS # |
186544-26-3
|
| Related CAS # |
LY 344864 S-enantiomer; 186544-27-4; LY 344864 racemate; 186543-64-6; LY 344864 hydrochloride; 1217756-94-9
|
| PubChem CID |
5311097
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
471.9±45.0 °C at 760 mmHg
|
| Flash Point |
239.2±28.7 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.658
|
| LogP |
3.43
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
26
|
| Complexity |
506
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O=C(NC1=CC2=C(NC3=C2C[C@H](N(C)C)CC3)C=C1)C4=CC=C(F)C=C4
|
| InChi Key |
OKUHLSYESBLBCP-PKLMIRHRSA-N
|
| InChi Code |
InChI=1S/C21H22FN3O.ClH/c1-25(2)16-8-10-20-18(12-16)17-11-15(7-9-19(17)24-20)23-21(26)13-3-5-14(22)6-4-13;/h3-7,9,11,16,24H,8,10,12H2,1-2H3,(H,23,26);1H/t16-;/m1./s1
|
| Chemical Name |
N-[(6R)-6-(dimethylamino)-6,7,8,9-tetrahydro-5H-carbazol-3-yl]-4-fluorobenzamide;hydrochloride
|
| Synonyms |
LY-344864; LY 344864; LY344864; LY-344864 free base
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~284.6 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.11 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.11 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.11 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8455 mL | 14.2276 mL | 28.4552 mL | |
| 5 mM | 0.5691 mL | 2.8455 mL | 5.6910 mL | |
| 10 mM | 0.2846 mL | 1.4228 mL | 2.8455 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
